{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.086","value":"1.10"},{"groupId":"OG001","spread":"24.175","value":"19.93"}]}],"title":"C reactive protein (CRP (mg/L))"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.604","value":"2.27"},{"groupId":"OG001","spread":"136.637","value":"71.09"}]}],"title":"Serum amyloid A (SAA (mg/L))"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"OG000","title":"ACZ885"},{"description":"Placebo subcutaneous injection every 8 weeks.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Intention to treat (ITT)population and LOCF.","reportingStatus":"POSTED","timeFrame":"Week 8 and Week 32","title":"Change in Inflammation Markers at the End of Part II (C-reactive Protein and/or Serum Amyloid A) (After 24 Weeks of the Double-blind Part) From Week 8.","type":"SECONDARY","unitOfMeasure":"mg/L"}